{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T06:35:21Z","timestamp":1794983721469,"version":"4.9.1"},"reference-count":46,"publisher":"American Association for Cancer Research (AACR)","issue":"24","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,12,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Lymphomas originate in and spread primarily along the lymphatic system. However, whether lymphatic vessels contribute to the growth and spreading of lymphomas is largely unclear. Mantle cell lymphoma (MCL) represents an aggressive non-Hodgkin's lymphoma. We found that MCL exhibited abundant intratumor lymphatic vessels. Our results demonstrated that the immunomodulatory drug lenalidomide potently inhibited the growth and dissemination of MCL in a xenograft MCL mouse model, at least in part, by inhibiting functional tumor lymphangiogenesis. Significant numbers of tumor-associated macrophages expressing vascular endothelial growth factor-C were found in both human MCL and mouse MCL xenograft samples. Lenalidomide treatment resulted in a significant reduction in the number of MCL-associated macrophages. In addition, in vivo depletion of monocytes\/macrophages impaired functional tumor lymphangiogenesis and inhibited MCL growth and dissemination. Taken together, our results indicate that tumor lymphangiogenesis contributes to the progression of MCL and that lenalidomide is effective in decreasing MCL growth and metastasis most likely by inhibiting recruitment of MCL-associated macrophages. Cancer Res; 73(24); 7254\u201364. \u00a92013 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-13-0750","type":"journal-article","created":{"date-parts":[[2013,10,25]],"date-time":"2013-10-25T04:20:10Z","timestamp":1382674810000},"page":"7254-7264","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Lenalidomide Inhibits Lymphangiogenesis in Preclinical Models of Mantle Cell Lymphoma"],"prefix":"10.1158","volume":"73","author":[{"given":"Kai","family":"Song","sequence":"first","affiliation":[{"name":"Authors' Affiliations:\u20081Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation; 2Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; 3Center for Lymphoma and Myeloma, Department of Medicine, Weill Cornell Medical College and New York-Presbyterian Hospital, New York City, New York; 4China-Japan Union Hospital of Jilin University, Changchun; 5Key Laboratory of Thrombosis and Hemostasis of Ministry of Health; and 6Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett H.","family":"Herzog","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation; 2Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; 3Center for Lymphoma and Myeloma, Department of Medicine, Weill Cornell Medical College and New York-Presbyterian Hospital, New York City, New York; 4China-Japan Union Hospital of Jilin University, Changchun; 5Key Laboratory of Thrombosis and Hemostasis of Ministry of Health; and 6Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjia","family":"Sheng","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation; 2Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; 3Center for Lymphoma and Myeloma, Department of Medicine, Weill Cornell Medical College and New York-Presbyterian Hospital, New York City, New York; 4China-Japan Union Hospital of Jilin University, Changchun; 5Key Laboratory of Thrombosis and Hemostasis of Ministry of Health; and 6Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China"},{"name":"Authors' Affiliations:\u20081Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation; 2Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; 3Center for Lymphoma and Myeloma, Department of Medicine, Weill Cornell Medical College and New York-Presbyterian Hospital, New York City, New York; 4China-Japan Union Hospital of Jilin University, Changchun; 5Key Laboratory of Thrombosis and Hemostasis of Ministry of Health; and 6Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxin","family":"Fu","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation; 2Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; 3Center for Lymphoma and Myeloma, Department of Medicine, Weill Cornell Medical College and New York-Presbyterian Hospital, New York City, New York; 4China-Japan Union Hospital of Jilin University, Changchun; 5Key Laboratory of Thrombosis and Hemostasis of Ministry of Health; and 6Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China"},{"name":"Authors' Affiliations:\u20081Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation; 2Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; 3Center for Lymphoma and Myeloma, Department of Medicine, Weill Cornell Medical College and New York-Presbyterian Hospital, New York City, New York; 4China-Japan Union Hospital of Jilin University, Changchun; 5Key Laboratory of Thrombosis and Hemostasis of Ministry of Health; and 6Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China"},{"name":"Authors' Affiliations:\u20081Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation; 2Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; 3Center for Lymphoma and Myeloma, Department of Medicine, Weill Cornell Medical College and New York-Presbyterian Hospital, New York City, New York; 4China-Japan Union Hospital of Jilin University, Changchun; 5Key Laboratory of Thrombosis and Hemostasis of Ministry of Health; and 6Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Michael","family":"McDaniel","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation; 2Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; 3Center for Lymphoma and Myeloma, Department of Medicine, Weill Cornell Medical College and New York-Presbyterian Hospital, New York City, New York; 4China-Japan Union Hospital of Jilin University, Changchun; 5Key Laboratory of Thrombosis and Hemostasis of Ministry of Health; and 6Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Ruan","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation; 2Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; 3Center for Lymphoma and Myeloma, Department of Medicine, Weill Cornell Medical College and New York-Presbyterian Hospital, New York City, New York; 4China-Japan Union Hospital of Jilin University, Changchun; 5Key Laboratory of Thrombosis and Hemostasis of Ministry of Health; and 6Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China"},{"name":"Authors' Affiliations:\u20081Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation; 2Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; 3Center for Lymphoma and Myeloma, Department of Medicine, Weill Cornell Medical College and New York-Presbyterian Hospital, New York City, New York; 4China-Japan Union Hospital of Jilin University, Changchun; 5Key Laboratory of Thrombosis and Hemostasis of Ministry of Health; and 6Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Xia","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation; 2Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; 3Center for Lymphoma and Myeloma, Department of Medicine, Weill Cornell Medical College and New York-Presbyterian Hospital, New York City, New York; 4China-Japan Union Hospital of Jilin University, Changchun; 5Key Laboratory of Thrombosis and Hemostasis of Ministry of Health; and 6Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China"},{"name":"Authors' Affiliations:\u20081Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation; 2Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; 3Center for Lymphoma and Myeloma, Department of Medicine, Weill Cornell Medical College and New York-Presbyterian Hospital, New York City, New York; 4China-Japan Union Hospital of Jilin University, Changchun; 5Key Laboratory of Thrombosis and Hemostasis of Ministry of Health; and 6Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China"},{"name":"Authors' Affiliations:\u20081Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation; 2Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; 3Center for Lymphoma and Myeloma, Department of Medicine, Weill Cornell Medical College and New York-Presbyterian Hospital, New York City, New York; 4China-Japan Union Hospital of Jilin University, Changchun; 5Key Laboratory of Thrombosis and Hemostasis of Ministry of Health; and 6Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China"},{"name":"Authors' Affiliations:\u20081Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation; 2Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; 3Center for Lymphoma and Myeloma, Department of Medicine, Weill Cornell Medical College and New York-Presbyterian Hospital, New York City, New York; 4China-Japan Union Hospital of Jilin University, Changchun; 5Key Laboratory of Thrombosis and Hemostasis of Ministry of Health; and 6Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2013,12,16]]},"reference":[{"key":"2022061703525890600_bib1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992\u20132001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"key":"2022061703525890600_bib2","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1365-2141.2005.05695.x","article-title":"Accelerated lymphangiogenesis in malignant lymphoma: possible role of VEGF-A and VEGF-C","volume":"130","author":"Kadowaki","year":"2005","journal-title":"Br J Haematol"},{"key":"2022061703525890600_bib3","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc2230","article-title":"Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics","volume":"7","author":"Jares","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"2022061703525890600_bib4","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","article-title":"Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma","volume":"145","author":"Habermann","year":"2009","journal-title":"Br J Haematol"},{"key":"2022061703525890600_bib5","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet Oncol"},{"key":"2022061703525890600_bib6","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","article-title":"Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma","volume":"26","author":"Wiernik","year":"2008","journal-title":"J Clin Oncol"},{"key":"2022061703525890600_bib7","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1200\/JCO.2008.21.1169","article-title":"Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma","volume":"27","author":"Witzig","year":"2009","journal-title":"J Clin Oncol"},{"key":"2022061703525890600_bib8","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","article-title":"Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-\u03b1","volume":"163","author":"Corral","year":"1999","journal-title":"J Immunol"},{"key":"2022061703525890600_bib9","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1182\/blood-2003-02-0361","article-title":"Immunomodulatory drug costimulates T cells via the B7-CD28 pathway","volume":"103","author":"LeBlanc","year":"2004","journal-title":"Blood"},{"key":"2022061703525890600_bib10","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.leukres.2010.09.027","article-title":"Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo","volume":"35","author":"Qian","year":"2011","journal-title":"Leuk Res"},{"key":"2022061703525890600_bib11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2141.2007.06841.x","article-title":"Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo","volume":"140","author":"Reddy","year":"2008","journal-title":"Br J Haematol"},{"key":"2022061703525890600_bib12","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells","volume":"14","author":"Wu","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2022061703525890600_bib13","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ajh.21468","article-title":"Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo","volume":"84","author":"Zhang","year":"2009","journal-title":"Am J Hematol"},{"key":"2022061703525890600_bib14","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1126\/science.1071420","article-title":"Lymphatic metastasis in the absence of functional intratumor lymphatics","volume":"296","author":"Padera","year":"2002","journal-title":"Science"},{"key":"2022061703525890600_bib15","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/nm.2545","article-title":"The lymphatic vasculature in disease","volume":"17","author":"Alitalo","year":"2011","journal-title":"Nat Med"},{"key":"2022061703525890600_bib16","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0002-9440(10)64255-1","article-title":"Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis","volume":"161","author":"Schoppmann","year":"2002","journal-title":"Am J Pathol"},{"key":"2022061703525890600_bib17","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1172\/JCI26354","article-title":"The crucial role of macrophages in lymphangiogenesis","volume":"115","author":"Kerjaschki","year":"2005","journal-title":"J Clin Invest"},{"key":"2022061703525890600_bib18","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1172\/JCI23874","article-title":"Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages","volume":"115","author":"Maruyama","year":"2005","journal-title":"J Clin Invest"},{"key":"2022061703525890600_bib19","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0145-2126(02)00013-9","article-title":"Establishment and characterization of a new mantle cell lymphoma cell line, Mino","volume":"26","author":"Lai","year":"2002","journal-title":"Leuk Res"},{"key":"2022061703525890600_bib20","doi-asserted-by":"crossref","first-page":"11406","DOI":"10.1073\/pnas.0610477104","article-title":"Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients","volume":"104","author":"Pellagatti","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061703525890600_bib21","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.4049\/jimmunol.174.10.6477","article-title":"Human lymphoid and myeloid cell development in NOD\/LtSz-SCID IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells","volume":"174","author":"Shultz","year":"2005","journal-title":"J Immunol"},{"key":"2022061703525890600_bib22","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.1038\/onc.2011.602","article-title":"Interaction of tumor cells and lymphatic vessels in cancer progression","volume":"31","author":"Alitalo","year":"2012","journal-title":"Oncogene"},{"key":"2022061703525890600_bib23","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1182\/blood-2012-08-447664","article-title":"Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment","volume":"121","author":"Schulz","year":"2013","journal-title":"Blood"},{"key":"2022061703525890600_bib24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(00)00255-2","article-title":"Mantle-cell lymphoma","volume":"2","author":"Barista","year":"2001","journal-title":"Lancet Oncol"},{"key":"2022061703525890600_bib25","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/84643","article-title":"Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis","volume":"7","author":"Skobe","year":"2001","journal-title":"Nat Med"},{"key":"2022061703525890600_bib26","first-page":"3233","article-title":"Interactions between endothelial selectins and cancer cells regulate metastasis. Front Biosci-Landmrk","volume":"16","author":"St Hill","year":"2011"},{"key":"2022061703525890600_bib27","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.cell.2010.01.045","article-title":"Lymphangiogenesis: molecular mechanisms and future promise","volume":"140","author":"Tammela","year":"2010","journal-title":"Cell"},{"key":"2022061703525890600_bib28","doi-asserted-by":"crossref","first-page":"e7067","DOI":"10.1371\/journal.pone.0007067","article-title":"Myeloid cells contribute to tumor lymphangiogenesis","volume":"4","author":"Zumsteg","year":"2009","journal-title":"PLoS One"},{"key":"2022061703525890600_bib29","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/nature04480","article-title":"Lymphangiogenesis in development and human disease","volume":"438","author":"Alitalo","year":"2005","journal-title":"Nature"},{"key":"2022061703525890600_bib30","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/nrc2444","article-title":"The role of myeloid cells in the promotion of tumour angiogenesis","volume":"8","author":"Murdoch","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"2022061703525890600_bib31","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood-2004-07-2947","article-title":"Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response","volume":"105","author":"Monti","year":"2005","journal-title":"Blood"},{"key":"2022061703525890600_bib32","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood-2005-04-1565","article-title":"Analysis of multiple biomarkers, shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL)","volume":"106","author":"Farinha","year":"2005","journal-title":"Blood"},{"key":"2022061703525890600_bib33","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"key":"2022061703525890600_bib34","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1002\/ijc.21579","article-title":"Mantle cell lymphomas acquire increased expression of CCL4, CCL5 and 4-1BB-L implicated in cell survival","volume":"118","author":"Ek","year":"2006","journal-title":"Int J Cancer"},{"key":"2022061703525890600_bib35","doi-asserted-by":"crossref","first-page":"240","DOI":"10.5603\/FHC.2011.0033","article-title":"Proinflammatory chemokine gene expression influences survival of patients with non-Hodgkin's lymphoma","volume":"49","author":"Mazur","year":"2011","journal-title":"Folia Histochem Cytobiol"},{"key":"2022061703525890600_bib36","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/jcp.21776","article-title":"CCL5 secreted by senescent aged fibroblasts induces proliferation of prostate epithelial cells and expression of genes that modulate angiogenesis","volume":"220","author":"Eyman","year":"2009","journal-title":"J Cell Physiol"},{"key":"2022061703525890600_bib37","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/sj.bjc.6603240","article-title":"Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach","volume":"95","author":"Zeisberger","year":"2006","journal-title":"Br J Cancer"},{"key":"2022061703525890600_bib38","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1083\/jcb.200903137","article-title":"Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3","volume":"188","author":"Xu","year":"2010","journal-title":"J Cell Biol"},{"key":"2022061703525890600_bib39","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ccr.2008.01.029","article-title":"Blocking neuropilin-2 function inhibits tumor cell metastasis","volume":"13","author":"Caunt","year":"2008","journal-title":"Cancer Cell"},{"key":"2022061703525890600_bib40","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1038\/sj.leu.2403058","article-title":"Thalidomide therapy induces response in relapsed mantle cell lymphoma","volume":"17","author":"Damaj","year":"2003","journal-title":"Leukemia"},{"key":"2022061703525890600_bib41","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood-2004-03-1091","article-title":"Antitumor activity of rituximab plus thalidomide in patients with relapsed\/refractory mantle cell lymphoma","volume":"104","author":"Kaufmann","year":"2004","journal-title":"Blood"},{"key":"2022061703525890600_bib42","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1056\/NEJMc1111010","article-title":"Myeloma and second primary cancers","volume":"365","author":"Landgren","year":"2011","journal-title":"N Engl J Med"},{"key":"2022061703525890600_bib43","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.pharmthera.2012.07.004","article-title":"The application and biology of immunomodulatory drugs (IMiDs) in cancer","volume":"136","author":"Pan","year":"2012","journal-title":"Pharmacol Ther"},{"key":"2022061703525890600_bib44","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3324\/haematol.2011.051813","article-title":"Salvage treatment with lenalidomide and dexamethasone in relapsed\/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers","volume":"97","author":"Zaja","year":"2012","journal-title":"Haematologica"},{"key":"2022061703525890600_bib45","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1749-6632.2002.tb04873.x","article-title":"Lymphatic vessel activation in cancer","volume":"979","author":"Cassella","year":"2002","journal-title":"Ann N Y Acad Sci"},{"key":"2022061703525890600_bib46","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1196\/annals.1413.021","article-title":"Lymphatic vessel activation in cancer","volume":"1131","author":"Das","year":"2008","journal-title":"Ann N Y Acad Sci"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/73\/24\/7254\/2691337\/7254.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/73\/24\/7254\/2691337\/7254.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T18:29:19Z","timestamp":1716056959000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/73\/24\/7254\/585272\/Lenalidomide-Inhibits-Lymphangiogenesis-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,15]]},"references-count":46,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2013,12,16]]},"published-print":{"date-parts":[[2013,12,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-13-0750","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6504512.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6504512","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22396223","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22396223.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,15]]}}}